Nilotinib is a Bcr-Abl inhibitor with IC50 less than 30 nM. It is under investigation as a possible treatment for chronic myelogenous leukemia (CML).
Products > Drug Discovery > Inhibitor | Products > Drug Discovery > Inhibitor | Cancer | Bcr-Abl
Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.